Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the
Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study
objectives are to confirm the treatment effect of pirfenidone compared with placebo on change
in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary
fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo
in patients with IPF.